How Eli Lilly is managing soaring demand for GLP-1s, according to outgoing CFO Anat Ashkenazi - CNBC

Ashkenazi has been key to managing the windfall in revenue and wave of investor optimism from Eli Lilly's diabetes injection Mounjaro and obesity drug Zepbound.